首页> 美国卫生研究院文献>British Heart Journal >Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)
【2h】

Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)

机译:口服雷帕霉素在进行冠状动脉支架置入术从头病变患者中预防再狭窄的作用:阿根廷单中心研究的结果(ORAR试验)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: To assess the role of oral rapamycin in the prevention of coronary restenosis in patients undergoing coronary stenting.>Methods: From December 2001 through February 2003, 76 patients with 103 de novo lesions treated percutaneously with bare stents received a loading dose of oral rapamycin 6 mg followed by a daily dose of 2 mg during 28 days in phase I (49 arteries in 34 patients) and 2 mg/day plus 180 mg/day of diltiazem in phase II (54 arteries in 42 patients). Rapamycin blood concentrations were measured in all patients. A six month follow up angiogram was performed in 82.5% (85 of 103 arteries). Follow up angiographic binary restenosis (> 50%), target vessel revascularisation, late loss, treatment compliance, and major adverse cardiovascular events were analysed and correlated with rapamycin concentrations.>Results: Rapamycin was well tolerated and only three patients discontinued the treatment for mild side effects. Angiographic restenosis was found in 15% of the arteries with angiographic restudy (13 of 85). The target vessel had been revascularised at follow up in 13.6% of the 103 vessels initially treated (14 of 103) and in 18.4% of the 76 patients (14 of 76). In-stent restenosis in phase I was 19% compared with 6.2% in phase II (p  =  0.06). Angiographic in-stent restenosis in lesions of patients with rapamycin blood concentrations ⩾ 8 ng/ml was 6.2% and with rapamycin concentrations < 8 ng/ml was 22% (p  =  0.041). Late loss was also significantly lower when rapamycin concentrations were ⩾ 8 ng/ml (0.6 mm v 1.1 mm, p  =  0.031). A Pearson test showed a linear correlation between follow up late loss and rapamycin blood concentration (r  =  −0.826, p  =  0.008).>Conclusion: Oral rapamycin administered for one month after percutaneous coronary intervention was safe and with few minor side effects. High rapamycin blood concentrations were associated with significantly lower late loss and angiographic in-stent restenosis.
机译:>目的::评估雷帕霉素在冠状动脉支架置入术中预防冠状动脉再狭窄的作用。>方法:从2001年12月至2003年2月,共有76例103例从头开始在第一阶段(28例患者中有49条动脉),在裸露的支架上经皮支架治疗的皮损接受负荷剂量的雷帕霉素6 mg口服治疗,随后每天口服2 mg雷帕霉素(在34例患者中有49条动脉),并在阶段每天2 mg /天加地尔硫卓180 mg II(42位患者中的54条动脉)。在所有患者中测量雷帕霉素的血液浓度。 82.5%(103个动脉中的85个)进行了6个月的随访血管造影。随访血管造影二值性再狭窄(> 50%),靶血管血运重建,晚期丢失,治疗依从性以及主要不良心血管事件,并将其与雷帕霉素浓度相关。>结果:雷帕霉素耐受性良好,只有3种患者因轻度副作用而终止治疗。在15%的血管造影再狭窄中发现了血管造影再狭窄(85中的13)。随访时,已对最初治疗的103例血管中的13.6%(103例中的14例)和76例患者中的14.4%(76例)中的目标血管进行了血管再通。第一阶段的支架内再狭窄为19%,而第二阶段为6.2%(p = 0.06)。雷帕霉素血药浓度≤8 ng / ml的患者的血管造影支架内再狭窄为6.2%,雷帕霉素血药浓度<8 ng / ml的患者为22%(p = 0.041)。当雷帕霉素浓度为⩾8 ng / ml(0.6 mm对1.1 mm,p = 0.031)时,后期损失也显着降低。皮尔逊检验显示随访后期损失与雷帕霉素血药浓度之间呈线性相关性(r = −0.826,p = 0.008)。>结论:经皮冠状动脉介入治疗后口服雷帕霉素是安全的,很少有副作用。雷帕霉素血药浓度高与明显减少的晚期丢失和血管造影支架内再狭窄有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号